Systemic AA Amyloidosis Following Immune Checkpoint Inhibitor Therapy for Lung Carcinosarcoma: An Autopsy Case and Review of the Literature.

Authors

Shinobu Onishi, Sari Iwasaki, Shimpei Nakagawa, Takuya Otsuka, Yuko Katayama, Satoshi Aoyama, Tetsuaki Shoji, Satoshi Tanaka, Jun Sakakibara-Konishi, Yoshihiro Matsuno, Shinya Tanaka, Koji Taniguchi

Published in

Internal medicine (Tokyo, Japan). Aug 25, 2026. Epub Aug 25, 2026.

Abstract

AA amyloidosis is a rare but serious complication of chronic inflammation. We report an autopsy case of a 68-year-old man without a documented history of inflammatory disease who developed lung carcinosarcoma and achieved a durable complete response after sequential immune checkpoint inhibitor (ICI) therapy. Despite tumor control, the patient developed a chronic intestinal pseudo-obstruction, persistent C-reactive protein elevation, progressive renal dysfunction, and later aspiration pneumonia. Autopsy revealed systemic AA amyloid deposition, predominantly in the intestines and kidneys, chronic thyroiditis, and tubulointerstitial nephritis. This case raises the possibility that prolonged inflammation during and after ICI therapy contributes to systemic AA amyloidosis.

PMID:
42649055
Bibliographic data and abstract were imported from PubMed on 27 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.